In this side of the Point/Counterpoint, Drs. Kelly and Knudsen state that limitations exist for guiding therapeutic treatment with genomic testing in prostate cancer patients.
W. Kevin Kelly, DO
Advertisement
Articles by W. Kevin Kelly, DO
We present a joint perspective from the medical oncology and urologic disciplines on the ongoing efforts to advance clinical trial performance in order to discover new therapies for this fatal disease.
Advertisement
Latest Updated Articles
The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3Published: February 15th 2016 | Updated:
COUNTERPOINT-Prostate Cancer Genomic Analysis: Routine or Research Only?Published: December 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
3
Response Rates Show Promise in Phase 1 trial Involving ASCT in Metastatic PDAC
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
